Pediatric Atopic Dermatitis (AD) Internet Survey

Atopic Dermatitis Clinical Trial

Official title:

Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01385527
• Other study ID #: IRB00016545
• Status: Withdrawn
• Phase: N/A
• Start date: June 2011
• Est. completion date: October 27, 2014

Study information

• Verified date: July 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 27, 2014
• Est. primary completion date: October 27, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 8 Years

Eligibility

Inclusion Criteria:

• Any child age 2 to 8 with a diagnosis of atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. Written consent must be given by parent/guardian.

Exclusion Criteria:

• Child is less than 2 or greater than 8 years of age.

• Known allergy or sensitivity to topical triamcinolone in the child.

• Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access.

• Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Subjects who are on systemic anti-inflammatory treatments for atopic dermatitis must be on a stable dose for at least 3 months prior to enrollment.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Behavioral:
• Weekly Internet survey
Parents will complete a weekly online survey about medication use.

Drug:
• Topical Triamcinolone
Topical triamcinolone to all affected areas once daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence to topical triamcinolone		12 weeks
Secondary	Eczema Area Severity Index		12 weeks
Secondary	Investigator's Global Assessment		12 weeks